The $24.5 Billion Vaccines Market in North America, 2019 to 2027 - Conjugate Vaccines Anticipated to Witness a Significant Growth Rate of 6.7% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 20, 2019--
The “North America Vaccines Market to 2027 - Regional Analysis and Forecasts by Technology; Disease Indication, Influenza, Hepatitis, Respiratory Syncytial Virus, and Other Diseases); Route of Administration; Patient Type, and Country” report has been added to ResearchAndMarkets.com’s offering.
The North America vaccines market is expected to reach US$ 24,510 Mn in 2027 from US$ 14,566 Mn in 2018. The market is estimated to grow with a CAGR of 6% from 2019-2027.
The growth of the vaccines market is primarily attributed due to the compulsion or mandate vaccination and dropping vaccination rates. However, low awareness about the benefits of vaccines are likely to hinder the growth of the market during the forecast period. Additionally the growth of the North America vaccines market is contributed due to the factors such as investments made by the key players for various research and development activities as well as launch of new products in the US.
In addition, extensive research in pharmaceutical and biotechnology companies further expected stimulate the growth of vaccines market in North America. The countries in the regions have face mandatory vaccinations legislation, the legislation was imposed to eradicate the deadly diseases such as measles, mumps and rubella vaccine from the country.
For instance, US has the highest prevalence of the measles, it is among the most contagious diseases approximately one out of nine is expected to get measles if he or she is not immune. As per the recent data shared by the Centers for Disease Control and Prevention (CDC) it is stated that in 2018 US experienced approximately 17 cases. In US, cities such as New York State, New Jersey, and New York City has registered three major outbreak of the measles.
Therefore, getting vaccinated or immunized is the best preventive measure thus, approximately in 50 states and the District of Columbia require students to be vaccinate before attending school. Owing to these factors the market is likely to grow significantly during the forecast period.
In 2018, the conjugate vaccines segment held a largest market share of 27.5% of the vaccines market, by technology. This segment is also expected to dominate the market in 2027 owing to advantages of the conjugate vaccines are their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. Moreover, the conjugate vaccines segment is anticipated to witness the significant growth rate of 6.7% during the forecast period, 2019 to 2027.
North America vaccines market by the disease indication was led by the others segments which has included diseases such as poliomyelitis (polio), measles, mumps, rubella, pneumococcal infections, and others. The segment has largest market share in 2018, which accounted 59.8% and is expected to dominate the market in 2027. Similarly, the vaccines market by the route of administration was led by the injectable segment. Whereas, the market of the vaccines in the North America by the patient type was led by the pediatric segment.
Some of the major primary and secondary sources for vaccines included in the report are Centers of Disease Control & Prevention, Food and Drug Administration, World Health Organization and Others.
Part 1. Introduction
Part 2. North America Vaccines Market - Key Takeaways
Part 3. North America Vaccines Market - Market Landscape
Part 4. North America Vaccines Market - Key Market Dynamics
4.1 Key Market Drivers
4.1.1 Compulsion or Mandate Vaccination
4.1.2 Dropping Vaccination Rates
4.2 Key Market Restraints
4.2.1 Low Awareness About the Benefits of Vaccines
4.3 Key Market Opportunities
4.3.1 Rising Numbers of Diseases
4.4 Future Trends
4.4.1 Advances In Vaccine Technology
4.5 Impact Analysis
Part 5. Vaccines Market - North America Analysis
5.1 North America Vaccines Market Revenue Forecasts and Analysis
5.2 Market Positioning
5.3 Performance of Key Players
Part 6. North America Vaccines Market Analysis - by Technology
6.2 North America Vaccines Market, by Type, 2018 & 2027 (%)
6.3 North America Vaccines Market Revenue and Forecasts To 2027, by Technology (US$ Mn)
6.4 North America Recombinant Vaccines Market
6.5 North America Conjugate Vaccines Market
6.6 North America Live Attenuated Vaccines Market
6.7 North America Inactivated Vaccines Market
6.8 North America Toxoid Vaccines Market
Part 7. North America Vaccines Market Analysis - by Disease Indication
7.2 North America Vaccines Market, by Disease Indication, 2018 & 2027 (%)
7.3 North America Vaccines Market Revenue and Forecasts To 2027, by Disease Indication (US$ Mn)
7.4 North America DTP (Diphtheria, Tetanus, and Pertussis) Market
7.5 North America Influenza Market
7.6 North America Hepatitis Market
7.7 North America Other Diseases Market
Part 8. North America Vaccines Market Analysis - by Route of Administration
8.2 North America Vaccines Market, by Route of Administration, 2018 & 2027 (%)
8.3 North America Vaccines Market Revenue and Forecasts To 2027, by Route of Administration (US$ Mn)
8.4 North America Oral Market
8.5 North America Injectable Market
8.6 North America Other Routes of Administration Market
Part 9. North America Vaccines Market Analysis - by Patient Type
9.2 North America Vaccines Market, by Patient Type, 2018 & 2027 (%)
9.3 North America Vaccines Market Revenue and Forecasts To 2027, by Patient Type (US$ Mn)
9.4 North America Pediatric Market
9.5 North America Adults Market
Part 10. North America Vaccines Market Revenue and Forecasts To 2027
Part 11. Vaccines Market - Industry Landscape
11.2 Comparative Company Analysis
11.3 Growth Strategies Done by the Companies In the Market, (%)
11.4 Organic Developments
11.5 Inorganic Developments
Part 12. Vaccines Market - Key Company Profiles
- Pfizer Inc.
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- Johnson & Johnson Services Inc.
- Panacea Biotec Limited
- Astellas Pharma Inc.
- Novavax Inc.
- VBI Vaccines Inc
- Bavarian Nordic.
For more information about this report visit https://www.researchandmarkets.com/r/gfv1du
View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005320/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: NORTH AMERICA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/20/2019 05:46 AM/DISC: 05/20/2019 05:46 AM